20 results on '"Hirsch, Etienne C."'
Search Results
2. Neuroprotection of dopamine neurons by xenon against low-level excitotoxic insults is not reproduced by other noble gases
- Author
-
Le Nogue, Déborah, Lavaur, Jérémie, Milet, Aude, Ramirez-Gil, Juan Fernando, Katz, Ira, Lemaire, Marc, Farjot, Géraldine, Hirsch, Etienne C., and Michel, Patrick Pierre
- Published
- 2020
- Full Text
- View/download PDF
3. The specific NQO2 inhibitor, S29434, only marginally improves the survival of dopamine neurons in MPTP-intoxicated mice.
- Author
-
Vallucci, Maeva, Boutin, Jean A., Janda, Elzbieta, Blandel, Florence, Musgrove, Ruth, Di Monte, Donato, Ferry, Gilles, Michel, Patrick P., and Hirsch, Etienne C.
- Subjects
DOPAMINERGIC neurons ,SUBSTANTIA nigra ,HUMAN body ,DOPAMINE receptors ,CELL death ,NEURODEGENERATION ,DOPAMINE ,NEUROTOXIC agents - Abstract
Over the years, evidence has accumulated on a possible contributive role of the cytosolic quinone reductase NQO2 in models of dopamine neuron degeneration induced by parkinsonian toxin, but most of the data have been obtained in vitro. For this reason, we asked the question whether NQO2 is involved in the in vivo toxicity of MPTP, a neurotoxin classically used to model Parkinson disease-induced neurodegeneration. First, we show that NQO2 is expressed in mouse substantia nigra dopaminergic cell bodies and in human dopaminergic SH-SY5Y cells as well. A highly specific NQO2 inhibitor, S29434, was able to reduce MPTP-induced cell death in a co-culture system of SH-SY5Y cells with astrocytoma U373 cells but was inactive in SH-SY5Y monocultures. We found that S29434 only marginally prevents substantia nigra tyrosine hydroxylase
+ cell loss after MPTP intoxication in vivo. The compound produced a slight increase of dopaminergic cell survival at day 7 and 21 following MPTP treatment, especially with 1.5 and 3 mg/kg dosage regimen. The rescue effect did not reach statistical significance (except for one experiment at day 7) and tended to decrease with the 4.5 mg/kg dose, at the latest time point. Despite the lack of robust protective activity of the inhibitor of NQO2 in the mouse MPTP model, we cannot rule out a possible role of the enzyme in parkinsonian degeneration, particularly because it is substantially expressed in dopaminergic neurons. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
4. The pRb/E2F Cell-Cycle Pathway Mediates Cell Death in Parkinson's Disease
- Author
-
Höglinger, Günter U., Breunig, Joshua J., Depboylu, Candan, Rouaux, Caroline, Michel, Patrick P., Alvarez-Fischer, Daniel, Boutillier, Anne-Laurence, DeGregori, James, Oertel, Wolfgang H., Rakic, Pasko, Hirsch, Etienne C., and Hunot, Stéphane
- Published
- 2007
- Full Text
- View/download PDF
5. Ten Unsolved Questions About Neuroinflammation in Parkinson's Disease.
- Author
-
Hirsch, Etienne C. and Standaert, David G.
- Abstract
Parkinson's disease is a progressive and debilitating disorder that has so far eluded attempts to develop disease-modifying treatment. Both epidemiological and genetic studies support a role of neuroinflammation in the pathophysiology of Parkinson's disease. Postmortem studies and experimental analyses suggest the involvement of both innate and adaptive immunity in the degenerative process. There is also some circumstantial evidence for effects of immune therapies on the disease. In the present article, we review 10 unanswered questions related to neuroinflammatory processes in Parkinson's disease with the goal of stimulating research in the field and accelerating the clinical development of neuroprotective therapies based on anti-inflammatory strategies. © 2020 International Parkinson and Movement Disorder Society. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. The noble gas xenon provides protection and trophic stimulation to midbrain dopamine neurons.
- Author
-
Lavaur, Jérémie, Le Nogue, Déborah, Lemaire, Marc, Pype, Jan, Farjot, Géraldine, Hirsch, Etienne C., and Michel, Patrick P.
- Subjects
XENON ,DOPAMINERGIC neurons ,NERVOUS system ,NEUROTRANSMITTERS ,BROMOCRIPTINE - Abstract
Despite its low chemical reactivity, the noble gas xenon possesses a remarkable spectrum of biological effects. In particular, xenon is a strong neuroprotectant in preclinical models of hypoxic-ischemic brain injury. In this study, we wished to determine whether xenon retained its neuroprotective potential in experimental settings that model the progressive loss of midbrain dopamine ( DA) neurons in Parkinson's disease. Using rat midbrain cultures, we established that xenon was partially protective for DA neurons through either direct or indirect effects on these neurons. So, when DA neurons were exposed to l- trans-pyrrolidine-2,4-dicarboxylic acid so as to increase ambient glutamate levels and generate slow and sustained excitotoxicity, the effect of xenon on DA neurons was direct. The vitamin E analog Trolox also partially rescued DA neurons in this setting and enhanced neuroprotection by xenon. However, in the situation where DA cell death was spontaneous, the protection of DA neurons by xenon appeared indirect as it occurred through the repression of a mechanism mediated by proliferating glial cells, presumably astrocytes and their precursor cells. Xenon also exerted trophic effects for DA neurons in this paradigm. The effects of xenon were mimicked and improved by the N-methyl- d-aspartate glutamate receptor antagonist memantine and xenon itself appeared to work by antagonizing N-methyl- d-aspartate receptors. Note that another noble gas argon could not reproduce xenon effects. Overall, present data indicate that xenon can provide protection and trophic support to DA neurons that are vulnerable in Parkinson's disease. This suggests that xenon might have some therapeutic value for this disorder. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
7. Understanding Dopaminergic Cell Death Pathways in Parkinson Disease.
- Author
-
Michel, Patrick P., Hirsch, Etienne C., and Hunot, Stéphane
- Subjects
- *
DOPAMINERGIC neurons , *CELL death , *PARKINSON'S disease , *NEURODEGENERATION , *SUBSTANTIA nigra , *PHYSIOLOGY - Abstract
Parkinson disease (PD) is a multifactorial neurodegenerative disorder, the etiology of which remains largely unknown. Progressive impairment of voluntary motor control, which represents the primary clinical feature of the disease, is caused by a loss of midbrain substantia nigra dopamine (DA) neurons. We present here a synthetic overview of cell-autonomous mechanisms that are likely to participate in DA cell death in both sporadic and inherited forms of the disease. In particular, we describe how damage to vulnerable DA neurons may arise from cellular disturbances produced by protein misfolding and aggregation, disruption of autophagic catabolism, endoplasmic reticulum (ER) stress, mitochondrial dysfunction, or loss of calcium homeostasis. Where pertinent, we show how these mechanisms may mutually cooperate to promote neuronal death. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
8. Heat shock protein 60: an endogenous inducer of dopaminergic cell death in Parkinson disease.
- Author
-
Noelker, Carmen, Morel, Lydie, Osterloh, Anke, Alvarez-Fischer, Daniel, Lescot, Thomas, Breloer, Minka, Gold, Maike, Oertel, Wolfgang H., Henze, Carmen, Michel, Patrick P., Dodel, Richard C., Lixia Lu, Hirsch, Etienne C., Hunot, Stéphane, and Hartmann, Andreas
- Subjects
HEAT shock proteins ,DOPAMINERGIC neurons ,CELL death ,PARKINSON'S disease patients ,MESSENGER RNA ,MESENCEPHALIC tegmentum - Abstract
Background Increasing evidence suggests that inflammation associated with microglial cell activation in the substantia nigra (SN) of patients with Parkinson disease (PD) is not only a consequence of neuronal degeneration, but may actively sustain dopaminergic (DA) cell loss over time. We aimed to study whether the intracellular chaperone heat shock protein 60 (Hsp60) could serve as a signal of CNS injury for activation of microglial cells. Methods Hsp60 mRNA expression in the mesencephalon and the striatum of C57/BL6 mice treated with MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and the Hsp60/TH mRNA ratios in the SN of PD patients and aged-matched subjects were measured. To further investigate a possible link between the neuronal Hsp60 response and PD-related cellular stress, Hsp60 immunoblot analysis and quantification in cell lysates from SH-SY5Y after treatment with 100 μM MPP
+ (1-methyl-4-phenylpyridinium) at different time points (6, 12, 24 and 48 hours) compared to control cells were performed. Additional MTT and LDH assay were used. We next addressed the question as to whether Hsp60 influences the survival of TH+ neurons in mesencephalic neuron-glia cultures treated either with MPP+ (1 μM), hHsp60 (10 μg/ml) or a combination of both. Finally, we measured IL-1β, IL-6, TNF-α and NO-release by ELISA in primary microglial cell cultures following treatment with different hHsp60 preparations. Control cultures were exposed to LPS. Results In the mesencephalon and striatum of mice treated with MPTP and also in the SN of PD patients, we found that Hsp60 mRNA was up-regulated. MPP+ , the active metabolite of MPTP, also caused an increased expression and release of Hsp60 in the human dopaminergic cell line SH-SY5Y. Interestingly, in addition to being toxic to DA neurons in primary mesencephalic cultures, exogenous Hsp60 aggravated the effects of MPP+ . Yet, although we demonstrated that Hsp60 specifically binds to microglial cells, it failed to stimulate the production of pro-inflammatory cytokines or NO by these cells. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
9. Specific needs of dopamine neurons for stimulation in order to survive: implication for Parkinson disease.
- Author
-
Michel, Patrick P., Toulorge, Damien, Guerretro, Serge, and Hirsch, Etienne C.
- Subjects
DOPAMINERGIC neurons ,SUBSTANTIA nigra ,CELL death ,NEURODEGENERATION ,NEURAL stimulation - Abstract
Parkinson disease (PD) is a degenerative brain disorder characterized by motor symptoms that are unequivocally associated with the loss of dopaminergic (DA) neurons in the substantia nigra (SN). Although our knowledge of the mechanisms that contribute to DA cell death in both hereditary and sporadic forms of the disease has advanced significantly, the nature of the pathogenic process remains poorly understood. In this review, we present evidence that neuro-degeneration occurs when the electrical activity and excitability of these neurons is reduced. In particular, we will focus on the specific need these neurons may have for stimulation in order to survive and on the molecular and cellular mechanisms that may be compromised when this need is no longer met in PD. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
10. DAP12 and CD11b contribute to the microglial-induced death of dopaminergic neurons in vitro but not in vivo in the MPTP mouse model of Parkinson's disease.
- Author
-
Kiyoka Kinugawa, Yann Monnet, Béchade, Catherine, Alvarez-Fischer, Daniel, Hirsch, Etienne C., Bessis, Alain, and Hunot, Stéphane
- Subjects
NEURODEGENERATION ,PARKINSON'S disease ,DOPAMINERGIC neurons ,SUBSTANTIA nigra ,CELL death ,METHYLPHENYLTETRAHYDROPYRIDINE ,MICROGLIA - Abstract
Background: Parkinson's disease (PD) is a neurodegenerative disorder characterized by a loss of dopaminergic neurons (DN) in the substantia nigra (SN). Several lines of evidence suggest that apoptotic cell death of DN is driven in part by non-cell autonomous mechanisms orchestrated by microglial cell-mediated inflammatory processes. Although the mechanisms and molecular network underlying this deleterious cross-talk between DN and microglial cells remain largely unknown, previous work indicates that, upon DN injury, activation of the β2 integrin subunit CD11b is required for microglia-mediated DN cell death. Interestingly, during brain development, the CD11b integrin is also involved in microglial induction of neuronal apoptosis and has been shown to act in concert with the DAP12 immunoreceptor. Whether such a developmental CD11b/DAP12 pathway could be reactivated in a pathological context such as PD and play a role in microglia-induced DN cell death is a tantalizing hypothesis that we wished to test in this study. Methods: To test the possibility that DAP12 could be involved in microglia-associated DN injury, we used both in vitro and in vivo toxin-based experimental models of PD recapitulating microglial-mediated non-cell autonomous mechanisms of DN cell death. In vitro, enriched mesencephalic neuronal/microglial co-cultures were exposed to the dopaminergic neurotoxin 1-methyl-4-phenylpyridinium (MPP+) whereas in vivo, mice were administrated with 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) according to acute or subchronic mode. Mice deficient for DAP12 or CD11b were used to determine the pathological function of the CD11b/DAP12 pathway in our disease models. Results: Our results show that DAP12 and CD11b partially contribute to microglia-induced DN cell death in vitro. Yet, in vivo, mice deficient for either of these factors develop similar neuropathological alterations as their wild-type counterparts in two different MPTP mouse models of PD. Conclusion: Overall, our data suggest that DAP12 and CD11b contribute to microglial-induced DN cell death in vitro but not in vivo in the MPTP mouse model of PD. Therefore, the CD11b/DAP12 pathway may not be considered as a promising therapeutic target for PD. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
11. Pathogenesis of Parkinson's disease.
- Author
-
Hirsch, Etienne C., Jenner, Peter, and Przedborski, Serge
- Abstract
Parkinson's disease is a common adult-onset neurodegenerative disorder whose pathogenesis remains essentially unknown. Currently, it is believed that the neurodegenerative process in Parkinson's disease is a combination of both cell-autonomous and non-cell-autonomous mechanisms. Proposed cell-autonomous mechanisms include alterations in mitochondrial bioenergetics, dysregulation of calcium homeostasis, and impaired turnover of mitochondria. As for the proposed non-cell-autonomous mechanisms, they involve prion-like behavior of misfolded proteins and neuroinflammation. This suggests that cell death in Parkinson's disease is caused by a multifactorial cascade of pathogenic events and argues that effective neuroprotective therapy for Parkinson's disease may have to rely on multiple drug interventions. © 2013 Movement Disorder Society [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
12. Neuroinflammation in Parkinson's disease: a target for neuroprotection?
- Author
-
Hirsch, Etienne C and Hunot, Stéphane
- Subjects
- *
NEURODEGENERATION , *SUBSTANTIA nigra , *OXIDATIVE stress , *CELL death , *IMMUNOLOGICAL adjuvants , *ANIMAL disease models , *AUTOPSY - Abstract
Summary: Parkinson''s disease is characterised by a slow and progressive degeneration of dopaminergic neurons in the substantia nigra. Despite intensive research, the cause of the neuronal loss in Parkinson''s disease is poorly understood. Neuroinflammatory mechanisms might contribute to the cascade of events leading to neuronal degeneration. In this Review, we describe the evidence for neuroinflammatory processes from post-mortem and in vivo studies in Parkinson''s disease. We further identify the cellular and molecular events associated with neuroinflammation that are involved in the degeneration of dopaminergic neurons in animal models of the disease. Overall, available data support the importance of non-cell-autonomous pathological mechanisms in Parkinson''s disease, which are mostly mediated by activated glial and peripheral immune cells. This cellular response to neurodegeneration triggers deleterious events (eg, oxidative stress and cytokine-receptor-mediated apoptosis), which might eventually lead to dopaminergic cell death and hence disease progression. Finally, we highlight possible therapeutic strategies (including immunomodulatory drugs and therapeutic immunisation) aimed at downregulating these inflammatory processes that might be important to slow the progression of Parkinson''s disease. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
13. Divalent metal transporter 1 (DM11) contributes to neurodegeneration in animal models of Parkinson's disease.
- Author
-
Salazar, Julio, Mena, Natalia, Hunot, Stephane, Prigent, Annick, Alvarez-Fischer, Daniel, Arredondo, Miguel, Duyckaerts, Charles, Sazdovitch, Veronique, Lin Zhao, Garrick, Laura M., Nuñez, Marco T., Garrick, Michael D., Raisman-Vozari, Rita, and Hirsch, Etienne C.
- Subjects
NEURODEGENERATION ,PARKINSON'S disease ,DOPAMINERGIC mechanisms ,NEUROGLIA ,CELL death - Abstract
Dopaminergic cell death in the substantia nigra (SN) is central to Parkinson's disease (PD), but the neurodegenerative mechanisms have not been completely elucidated. Iron accumulation in dopaminergic and glial cells in the SN of PD patients may contribute to the generation of oxidative stress, protein aggregation, and neuronal death. The mechanisms involved in iron accumulation also remain unclear. Here, we describe an increase in the expression of an isoform of the divalent metal transporter 1 (DMT1/Nramp2/Slc11a2) in the SN of PD patients. Using the PD animal model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication in mice, we showed that DMT1 expression increases in the ventral mesencephalon of intoxicated animals, concomitant with iron accumulation, oxidative stress, and dopaminergic cell loss. In addition, we report that a mutation in DMT1 that impairs iron transport protects rodents against parkinsonism-inducing neurotoxins MPTP and 6-hydroxydopamine. This study supports a critical role for DMT1 in iron-mediated neurodegeneration in PD [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
14. Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid.
- Author
-
Alvarez-Fischer, Daniel, Guerreiro, Serge, Hunot, Stéphane, Saurini, Françoise, Marien, Marc, Sokoloff, Pierre, Hirsch, Etienne C., Hartmann, Andreas, and Michel, Patrick P.
- Subjects
LEWY body dementia ,ALCOHOLISM ,TEMPERANCE ,PARKINSON'S disease ,NEURODEGENERATION ,DOPAMINERGIC neurons ,CELL death - Abstract
Mouse models of MPTP intoxication have been used extensively to explore the molecular mechanisms of Parkinson’s disease. However, these models present some limitations since; (i) Dopaminergic (DA) cell death occurs rapidly in contrast to the presumably slow evolution of the disease process. (ii) Some of the key histological features of the disease such as Lewy body like inclusions and long-term inflammatory changes are lacking. Fornai et al. [ Proc. Natl Acad. Sci. USA 102 (2005), 3413] suggested that continuous delivery of MPTP with Alzet osmotic minipumps may possibly circumvent these problems. Our results show, however, that MPTP infusion via Alzet osmotic minipumps (40 mg/kg/day) produces only a transient depletion in striatal dopamine (DA) without causing dopaminergic cell loss in the substantia nigra. Neuronal cell loss occurred, however, if MPTP was infused concomitantly with probenecid, an uricosuric agent which potentiates the effects of the toxin injected via the i.p. route. Even under these conditions, dopaminergic cell loss was moderate (−25%) and other neurodegenerative changes characteristic of Parkinson’s disease remained undetectable. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
15. Annonacin, a Natural Mitochondrial Complex I Inhibitor, Causes Tau Pathology in Cultured Neurons.
- Author
-
Escobar-Khondiker, Myriam, Höllerhage, Matthias, Muriel, Marie-Paule, Champy, Pierre, Bach, Antoine, Depienne, Christel, Respondek, Gesine, Yamada, Elizabeth S., Lannuzel, Annie, Yagi, Takao, Hirsch, Etienne C., Oertel, Wolfgang H., Jacob, Ralf, Michel, Patrick P., Ruberg, Merle, and Höglinger, Günter U.
- Subjects
ANNONACEAE ,POLYKETIDES ,MITOCHONDRIA ,NEURODEGENERATION ,SACCHAROMYCES cerevisiae ,NEUROTOXIC agents ,GLYCOLYSIS - Abstract
A neurodegenerative tauopathy endemic to the Caribbean island of Guadeloupe has been associated with the consumption of anonaceous plants that contain acetogenins, potent lipophilic inhibitors of complex I of the mitochondrial respiratory chain. To test the hypothesis that annonacin, a prototypical acetogenin, contributes to the etiology of the disease, we investigated whether annonacin affects the cellular distribution of the protein tau. In primary cultures of rat striatal neurons treated for 48 h with annonacin, there was a concentration-dependent decrease in ATP levels, a redistribution of tau from the axons to the cell body, and cell death. Annonacin induced the retrograde transport of mitochondria, some of which had tau attached to their outer membrane. Taxol, a drug that displaces tau from microtubules, prevented the somatic redistribution of both mitochondria and tau but not cell death. Antioxidants, which scavenged the reactive oxygen species produced by complex I inhibition, did not affect either the redistribution of tau or cell death. Both were prevented, however, by forced expression of the NDI1 nicotinamide adenine dinucleotide (NADH)-quinone-oxidoreductase of Saccharomyces cerevisiae, which can restore NADH oxidation in complex I-deficient mammalian cells and stimulation of energy production via anaerobic glycolysis. Consistently, other ATP-depleting neurotoxins (1-methyl-4-phenylpyridinium, 3-nitropropionic, and carbonyl cyanide m-chlorophenylhydrazone) reproduced the somatic redistribution of tau, whereas toxins that did not decrease ATP levels did not cause the redistribution of tau. Therefore, the annonacin-induced ATP depletion causes the retrograde transport of mitochondria to the cell soma and induces changes in the intracellular distribution of tau in a way that shares characteristics with some neurodegenerative diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
16. Donepezil induces a cholinergic sprouting in basocortical degeneration.
- Author
-
Ginestet, Laure, Ferrario, Juan E., Raisman-Vozari, Rita, Hirsch, Etienne C., and Debeir, Thomas
- Subjects
NEURODEGENERATION ,CHOLINESTERASES ,ALZHEIMER'S disease ,ACETYLCHOLINESTERASE ,PRESENILE dementia ,ACETYLCHOLINE ,NEUROTRANSMITTERS - Abstract
One of the few currently approved therapies for Alzheimer’s disease (AD) consists in the administration of acetylcholinesterase inhibitors, which enhances the lifetime of the neurotransmitter acetylcholine. Despite numerous studies on the symptomatic effect of acetylcholinesterase inhibitors, there is as yet no direct morphological evidence to indicate that they have a neurorestorative action. We investigated the effect of the acetylcholinesterase inhibitor donepezil administered subcutaneously in a rat model of partial unilateral cortical devascularization that induces a loss of the cortical cholinergic terminal network and a retrograde degeneration of the cholinergic projections that originate in the nucleus basalis. For 6 weeks, lesioned and sham-operated rats received a subcutaneous infusion of donepezil (2 mg/kg/day) or vehicle, delivered by osmotic minipumps implanted 2 weeks before the cortical devascularization. In lesioned rats, donepezil treatment increased the number and the size of vesicular acetylcholine transporter immunoreactive boutons in comparison to vehicle treatment. Donepezil had no observable effect on any of these parameters in sham-operated animals. These results show that donepezil mitigates cholinergic neuronal degeneration in vivo. This suggests a neuroplastic activity of this drug and provides evidence for a potential use of donepezil as a disease modifier in neurodegenerative diseases such as AD. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
17. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease.
- Author
-
Hunot, Stéphane, Vila, Miquel, Teismann, Peter, Davis, Roger J., Hirsch, Etienne C., Przedborski, Serge, Rakic, Pasko, and Flavell, Richard A.
- Subjects
PARKINSON'S disease ,NEURODEGENERATION ,DOPAMINE ,NEURONS ,MESENCEPHALON ,NERVOUS system ,GENETIC mutation - Abstract
Parkinson's disease (PD) is a common neurodegenerative disorder characterized by selective and progressive demise of dopamine-containing neurons in the midbrain. Although mutated genes have been identified in some cases of inherited PD, genetic origin could not be found in most cases, which occur sporadically. Despite extensive investigations, the cause of PD remains unknown. Undoubtedly, the design of effective treatments for PD depends largely on understanding of the molecular mechanisms leading to neurodegeneration, which is still incomplete.
- Published
- 2004
- Full Text
- View/download PDF
18. Neuroinflammation in Parkinson's disease
- Author
-
Hirsch, Etienne C., Vyas, Sheela, and Hunot, Stéphane
- Subjects
- *
PARKINSON'S disease , *INFLAMMATION , *EPIDEMIOLOGY , *T cells , *NEURODEGENERATION , *NEUROIMMUNOLOGY , *PATHOLOGICAL physiology - Abstract
Summary: Both epidemiological and genetic studies support a role of neuroinflammation in the pathophysiology of Parkinson''s disease (PD). Furthermore, post mortem studies confirm the involvement of innate as well as adaptive immunity in the affected brain regions in patients with PD. Indeed, activated microglial cells and T lymphocytes have been detected in the substantia nigra of patients concomitantly with an increased expression of pro-inflammatory mediators. Preclinical investigations conducted in various animal models of PD indicate that inflammatory processes are instrumental in neuronal cell death even though they are unlikely to be a primary cause for neuronal loss. Neuroinflammatory processes in PD are rather involved in self-perpetuating deleterious events that lead to protracted neuronal degeneration. In line with this, recent data indicate that glucocorticoid receptors are important in curtailing microglial reactivity, and deregulation in their activity in PD could lead to sustained inflammation-mediated degeneration. Altogether, neuroinflammatory processes might represent a target for neuroprotection in PD. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
19. MFGE8 does not orchestrate clearance of apoptotic neurons in a mouse model of Parkinson's disease
- Author
-
Kinugawa, Kiyoka, Monnet, Yann, Lu, Lixia, Bekaert, Amaury J., Théry, Clotilde, Mallat, Ziad, Hirsch, Etienne C., and Hunot, Stéphane
- Subjects
- *
PARKINSON'S disease , *ANIMAL models in research , *MILKFAT , *EPIDERMAL growth factor , *APOPTOSIS , *DOPAMINERGIC neurons , *NEURODEGENERATION , *LABORATORY mice , *AGE factors in disease - Abstract
Abstract: Parkinson''s disease (PD) is an age-related neurodegenerative disorder characterized by a loss of dopaminergic neurons (DN) in the substantia nigra (SN). Several lines of evidence suggest that apoptotic cell death of DN is driven in part by non-cell autonomous mechanisms implicating microglial cells and inflammatory processes. Yet, how apoptotic DNs get removed by professional phagocytes and how this process modulates inflammatory processes are still unresolved issues. In this study, we investigated the role of MFGE8, a soluble factor involved in phagocytic recognition, in apoptotic DN clearance and neuroinflammation in PD. We report that glial expression of MFGE8 is enhanced in post-mortem PD brains compared to control individuals. Then, in vivo functional analysis of Mfge8 was assessed in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxicated mouse model of PD using wild-type (WT) and Mfge8-deficient mice. Neuropathological analysis consisted in evaluating (i) the loss of nigral DN and striatal DN terminals, (ii) the extent of glial cell activation and (iii) the number of apoptotic profiles. In vivo microglial phagocytic activity was further assessed by measuring the engulfment of apoptotic DN preloaded with fluorescent latex beads. Here we show that Mfge8 deficiency neither impact the phagocytic clearance of apoptotic bodies nor change the overall neuropathological parameters (DN cell loss and glial cell activation). In summary, our data argue that MFGE8 is not likely involved in the phagocytic clearance of neuronal debris associated with nigrostriatal pathway injury. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
20. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease.
- Author
-
Brochard, Vanessa, Combadière, Béhazine, Prigent, Annick, Laouar, Yasmina, Perrin, Aline, Beray-Berthat, Virginie, Bonduelle, Olivia, Alvarez-Fischer, Daniel, Callebert, Jacques, Launay, Jean-Marie, Duyckaerts, Charles, Flavell, Richard A., Hirsch, Etienne C., Hunot, Stéphane, Combadière, Béhazine, and Hunot, Stéphane
- Subjects
- *
PARKINSON'S disease , *NEURODEGENERATION , *DOPAMINE , *NEURONS , *LYMPHOCYTES , *IMMUNE system , *PROTEIN metabolism , *ANIMAL experimentation , *BIOLOGICAL models , *BRAIN , *CELL death , *COMPARATIVE studies , *INTERFERONS , *RESEARCH methodology , *MEDICAL cooperation , *MICE , *PROTEINS , *RESEARCH , *T cells , *EVALUATION research , *PARKINSONIAN disorders ,IMMUNE system physiology - Abstract
Parkinson disease (PD) is a neurodegenerative disorder characterized by a loss of dopamine-containing neurons. Mounting evidence suggests that dopaminergic cell death is influenced by the innate immune system. However, the pathogenic role of the adaptive immune system in PD remains enigmatic. Here we showed that CD8+ and CD4+ T cells but not B cells had invaded the brain in both postmortem human PD specimens and in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD during the course of neuronal degeneration. We further demonstrated that MPTP-induced dopaminergic cell death was markedly attenuated in the absence of mature T lymphocytes in 2 different immunodeficient mouse strains (Rag1-/- and Tcrb-/- mice). Importantly, similar attenuation of MPTP-induced dopaminergic cell death was seen in mice lacking CD4 as well as in Rag1-/- mice reconstituted with FasL-deficient splenocytes. However, mice lacking CD8 and Rag1-/- mice reconstituted with IFN-gamma-deficient splenocytes were not protected. These data indicate that T cell-mediated dopaminergic toxicity is almost exclusively arbitrated by CD4+ T cells and requires the expression of FasL but not IFNgamma. Further, our data may provide a rationale for targeting the adaptive arm of the immune system as a therapeutic strategy in PD. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.